In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Eli Lilly says a new pill for obesity, similar to existing GLP-1 medications that can only be injected, is showing promise in ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Drugmaker Eli Lilly said Thursday that things are looking good for their latest weight loss drug that would be available as a ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and ...